Literature DB >> 14767978

Targeting portal pressure measurements: a critical reappraisal.

Ulrich Thalheimer1, Maria Mela, David Patch, Andrew K Burroughs.   

Abstract

Many of the complications of cirrhosis reflect the presence of portal hypertension, which is commonly expressed as the hepatic venous pressure gradient (HVPG). Baseline and repeat measurements of HVPG have been recommended for the management of patients with cirrhosis in the setting of pharmacologic prophylaxis of variceal bleeding and for gaining information about prognosis. However, published studies have demonstrated problems with the interpretation of the data on HVPG monitoring, making its use controversial. We view the current data as insufficient evidence to support the monitoring of a targeted reduction of HVPG as routine clinical practice. We recommend the performance of new prospective studies to establish the clinical importance of HVPG measurements.

Entities:  

Mesh:

Year:  2004        PMID: 14767978     DOI: 10.1002/hep.20061

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  13 in total

1.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Authors:  Al B Benson; Thomas A Abrams; Edgar Ben-Josef; P Mark Bloomston; Jean F Botha; Bryan M Clary; Anne Covey; Steven A Curley; Michael I D'Angelica; Rene Davila; William D Ensminger; John F Gibbs; Daniel Laheru; Mokenge P Malafa; Jorge Marrero; Steven G Meranze; Sean J Mulvihill; James O Park; James A Posey; Jasgit Sachdev; Riad Salem; Elin R Sigurdson; Constantinos Sofocleous; Jean-Nicolas Vauthey; Alan P Venook; Laura Williams Goff; Yun Yen; Andrew X Zhu
Journal:  J Natl Compr Canc Netw       Date:  2009-04       Impact factor: 11.908

2.  Use of portal pressure studies in the management of variceal haemorrhage.

Authors:  Jennifer Addley; Tony Ck Tham; William Jonathan Cash
Journal:  World J Gastrointest Endosc       Date:  2012-07-16

3.  Assessment of risk of complications in cirrhosis using portal thallium scans.

Authors:  Hye-Jin Tae; Dae-Won Jun; Yun-Young Choi; Min-Jung Kwak; Min-Ho Lee
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

4.  Hemodynamic Response to Carvedilol is Maintained for Long Periods and Leads to Better Clinical Outcome in Cirrhosis: A Prospective Study.

Authors:  Vijendra Kirnake; Anil Arora; Varun Gupta; Praveen Sharma; Vikas Singla; Naresh Bansal; Mohan Goyal; Romesh Chawlani; Ashish Kumar
Journal:  J Clin Exp Hepatol       Date:  2016-01-23

5.  Contrast-enhanced ultrasonography (CEUS) immediately after percutaneous ablation of hepatocellular carcinoma.

Authors:  A Gallotti; M D'Onofrio; A Ruzzenente; E Martone; R De Robertis; A Guglielmi; R Pozzi Mucelli
Journal:  Radiol Med       Date:  2009-09-05       Impact factor: 3.469

Review 6.  Pharmacologic therapy for gastrointestinal bleeding due to portal hypertension and esophageal varices.

Authors:  Don C Rockey
Journal:  Curr Gastroenterol Rep       Date:  2006-02

Review 7.  Variceal bleeding : pharmacological treatment and prophylactic strategies.

Authors:  Cándid Villanueva; Joaquim Balanzó
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Hepatic venous pressure gradient in cirrhosis: correlation with the size of varices, bleeding, ascites, and child's status.

Authors:  M Wadhawan; S Dubey; B C Sharma; S K Sarin; S K Sarin
Journal:  Dig Dis Sci       Date:  2006-11-01       Impact factor: 3.487

Review 9.  Beta-blockers in liver cirrhosis.

Authors:  Valerio Giannelli; Barbara Lattanzi; Ulrich Thalheimer; Manuela Merli
Journal:  Ann Gastroenterol       Date:  2014

10.  Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade.

Authors:  Hidenori Toyoda; Paul B S Lai; James O'Beirne; Charing C Chong; Sarah Berhane; Helen Reeves; Derek Manas; Richard P Fox; Winnie Yeo; Frankie Mo; Anthony W H Chan; Toshifumi Tada; Mercedes Iñarrairaegui; Arndt Vogel; Nora Schweitzer; Stephen L Chan; Bruno Sangro; Takashi Kumada; Philip J Johnson
Journal:  Br J Cancer       Date:  2016-03-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.